{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:07:49Z","timestamp":1790356069480,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10147-026-03170-4","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:03:19Z","timestamp":1786982599000},"page":"2087-2094","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacotherapy for older adults with cancer: a digest of the Japanese clinical practice guidelines (2nd edition)\u2014general principles"],"prefix":"10.1007","volume":"31","author":[{"given":"Hirofumi","family":"Ohmura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8907-3166","authenticated-orcid":false,"given":"Hiroshi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Mizutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Enokido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusei","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumio","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumu","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asao","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the JSMO\/JSCO Clinical Practice Guideline Committee on Pharmacotherapy for Older Adults with Cancer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"issue":"22","key":"3170_CR1","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1200\/JCO.19.02809","volume":"38","author":"C DuMontier","year":"2020","unstructured":"DuMontier C, Loh KP, Bain PA et al (2020) Defining undertreatment and overtreatment in older adults with cancer: a scoping literature review. J Clin Oncol 38(22):2558\u20132569","journal-title":"J Clin Oncol"},{"issue":"2","key":"3170_CR2","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1200\/JCO.2002.20.2.494","volume":"20","author":"L Repetto","year":"2002","unstructured":"Repetto L, Fratino L, Audisio RA et al (2002) Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol 20(2):494\u2013502","journal-title":"J Clin Oncol"},{"issue":"4","key":"3170_CR3","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1634\/theoncologist.2014-0247","volume":"20","author":"TA Jolly","year":"2015","unstructured":"Jolly TA, Deal AM, Nyrop KA et al (2015) Geriatric assessment-identified deficits in older cancer patients with normal performance status. Oncologist 20(4):379\u2013385","journal-title":"Oncologist"},{"issue":"5","key":"3170_CR4","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.jgo.2018.03.014","volume":"9","author":"ME Hamaker","year":"2018","unstructured":"Hamaker ME, Te Molder M, Thielen N et al (2018) The effect of a geriatric evaluation on treatment decisions and outcome for older cancer patients\u2014a systematic review. J Geriatr Oncol 9(5):430\u2013440","journal-title":"J Geriatr Oncol"},{"issue":"10","key":"3170_CR5","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1200\/JCO.2010.30.6985","volume":"29","author":"A Hurria","year":"2011","unstructured":"Hurria A, Cirrincione CT, Muss HB et al (2011) Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401. J Clin Oncol 29(10):1290\u20131296","journal-title":"J Clin Oncol"},{"issue":"1","key":"3170_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1200\/JCO.2013.51.1345","volume":"32","author":"C Kenis","year":"2014","unstructured":"Kenis C, Decoster L, Van Puyvelde K et al (2014) Performance of two geriatric screening tools in older patients with cancer. J Clin Oncol 32(1):19\u201326","journal-title":"J Clin Oncol"},{"issue":"24","key":"3170_CR7","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1200\/JCO.2013.54.8347","volume":"32","author":"H Wildiers","year":"2014","unstructured":"Wildiers H, Heeren P, Puts M et al (2014) International society of geriatric oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol 32(24):2595\u20132603","journal-title":"J Clin Oncol"},{"issue":"22","key":"3170_CR8","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1200\/JCO.2018.78.8687","volume":"36","author":"SG Mohile","year":"2018","unstructured":"Mohile SG, Dale W, Somerfield MR et al (2018) Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology. J Clin Oncol 36(22):2326\u20132347","journal-title":"J Clin Oncol"},{"key":"3170_CR9","unstructured":"National Comprehensive Cancer Network (2026) NCCN clinical practice guidelines in oncology: older adult oncology. Older Adult Oncology Version 1. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/older_adult.pdf"},{"issue":"10314","key":"3170_CR10","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1016\/S0140-6736(21)01789-X","volume":"398","author":"SG Mohile","year":"2021","unstructured":"Mohile SG, Mohamed MR, Xu H et al (2021) Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study. Lancet 398(10314):1894\u20131904","journal-title":"Lancet"},{"issue":"2","key":"3170_CR11","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1001\/jamaoncol.2019.4728","volume":"6","author":"SG Mohile","year":"2020","unstructured":"Mohile SG, Epstein RM, Hurria A et al (2020) Communication with older patients with cancer using geriatric assessment: a cluster-randomized clinical trial from the National Cancer Institute Community Oncology Research Program. JAMA Oncol 6(2):196\u2013204","journal-title":"JAMA Oncol"},{"issue":"11","key":"3170_CR12","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.4158","volume":"7","author":"D Li","year":"2021","unstructured":"Li D, Sun CL, Kim H et al (2021) Geriatric assessment-driven intervention (GAIN) on chemotherapy-related toxic effects in older adults with cancer: a randomized clinical trial. JAMA Oncol 7(11):e214158","journal-title":"JAMA Oncol"},{"issue":"9","key":"3170_CR13","doi-asserted-by":"publisher","first-page":"e617","DOI":"10.1016\/S2666-7568(22)00169-6","volume":"3","author":"WK Soo","year":"2022","unstructured":"Soo WK, King MT, Pope A et al (2022) Integrated geriatric assessment and treatment effectiveness (INTEGERATE) in older people with cancer starting systemic anticancer treatment in Australia: a multicentre, open-label, randomised controlled trial. Lancet Healthy Longev 3(9):e617\u2013e627","journal-title":"Lancet Healthy Longev"},{"issue":"26","key":"3170_CR14","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1200\/JCO.23.00933","volume":"41","author":"W Dale","year":"2023","unstructured":"Dale W, Klepin HD, Williams GR et al (2023) Practical assessment and management of vulnerabilities in older patients receiving systemic cancer therapy: ASCO guideline update. J Clin Oncol 41(26):4293\u20134312","journal-title":"J Clin Oncol"},{"key":"3170_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-026-03100-4","author":"A Matsuoka","year":"2026","unstructured":"Matsuoka A, Nagashima F, Ogawa A et al (2026) Japanese clinical practice guidelines for pharmacotherapy in older adults with cancer (second edition): an overview. Int J Clin Oncol. https:\/\/doi.org\/10.1007\/s10147-026-03100-4","journal-title":"Int J Clin Oncol"},{"issue":"2","key":"3170_CR16","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s00520-017-3874-6","volume":"26","author":"A Magnuson","year":"2018","unstructured":"Magnuson A, Lemelman T, Pandya C et al (2018) Geriatric assessment with management intervention in older adults with cancer: a randomized pilot study. Support Care Cancer 26(2):605\u2013613","journal-title":"Support Care Cancer"},{"issue":"3","key":"3170_CR17","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.jgo.2019.06.019","volume":"11","author":"S Nadaraja","year":"2020","unstructured":"Nadaraja S, Matzen LE, J\u00f8rgensen TL et al (2020) The impact of comprehensive geriatric assessment for optimal treatment of older patients with cancer: a randomized parallel-group clinical trial. J Geriatr Oncol 11(3):488\u2013495","journal-title":"J Geriatr Oncol"},{"issue":"4","key":"3170_CR18","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1200\/JCO.22.01007","volume":"41","author":"M Puts","year":"2023","unstructured":"Puts M, Alqurini N, Strohschein F et al (2023) Impact of geriatric assessment and management on quality of life, unplanned hospitalizations, toxicity, and survival for older adults with cancer: the randomized 5C trial. J Clin Oncol 41(4):847\u2013858","journal-title":"J Clin Oncol"},{"issue":"1","key":"3170_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2023.101658","volume":"15","author":"AW Giger","year":"2024","unstructured":"Giger AW, Ditzel HM, Ditzel HJ et al (2024) Effects of comprehensive geriatric assessment-guided interventions on physical performance and quality of life in older patients with advanced cancer: a randomized controlled trial (PROGNOSIS-RCT). J Geriatr Oncol 15(1):101658","journal-title":"J Geriatr Oncol"},{"issue":"13","key":"3170_CR20","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1200\/JCO.2015.63.5839","volume":"34","author":"R Corre","year":"2016","unstructured":"Corre R, Greillier L, Le Ca\u00ebr H et al (2016) Use of a comprehensive geriatric assessment for the management of elderly patients with advanced non-small-cell lung cancer: the phase III randomized ESOGIA-GFPC-GECP 08-02 study. J Clin Oncol 34(13):1476\u20131483","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03170-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03170-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03170-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:50:17Z","timestamp":1790355017000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-03170-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["3170"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03170-4","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]},"assertion":[{"value":"23 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have completed the conflict-of-interest disclosure in accordance with the requirements of the International Journal of Clinical Oncology and the policy of the Japanese Society of Medical Oncology. The disclosures were reviewed by the society\u2019s conflict-of-interest committee to ensure appropriate participation in the guideline development process. The following potential conflicts of interest are disclosed: A.O. reports honoraria from Chugai Pharmaceutical Co., Ltd. and Eisai Co., Ltd. H.Y. reports honoraria from AstraZeneca K.K., Kyorin Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., MSD K.K., Pfizer Japan Inc., Kyowa Kirin Co., Ltd., Amgen K.K., GlaxoSmithKline K.K., Daiichi Sankyo Co., Ltd., Teijin Healthcare Limited, Sanofi K.K., Insmed Incorporated, Bristol-Myers Squibb K.K., Nippon Kayaku Co., Ltd., and Life Technologies Japan Ltd.; fees for promotional materials from Chugai Pharmaceutical Co., Ltd. and bioM\u00e9rieux Japan Ltd.; and research funding from AstraZeneca K.K., Kyorin Pharmaceutical Co., Ltd., CES Decartes, and Ono Pharmaceutical Co., Ltd. F.N. reports honoraria from Taiho Pharmaceutical, Ono Pharmaceutical, Takeda Pharmaceutical, Chugai Pharmaceutical, Yakult Honsha, Janssen, Merck, and Daiichi Sankyo; and research funding from Ono Pharmaceutical, OncoTherapy Science, Merck Serono, Zeria Pharmaceutical, Eli Lilly, Takeda Pharmaceutical, Chugai Pharmaceutical, Yakult Honsha, Sumitomo Pharma, Daiichi Sankyo, Shionogi, J-Pharma, Bristol-Myers Squibb, Kyowa Kirin, Mochida Pharmaceutical, Astellas Pharma, Bayer, MSD, Eisai, NanoCarrier, Janssen, Baxalta\/Shire, and Novartis. A.M. reports honoraria from Chugai Pharmaceutical and Taiho Pharmaceutical. The other authors declare no conflicts of interest.","order":3,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}